Research and Development

Biocartis, a Swiss company developing compact molecular diagnostic systems, has announced the appointment of Dr Nayan Gregory Parekh as its …

Lilly has appointed Richard Ascroft as senior director, corporate affairs, for the Australia, Canada and Europe (ACE) region. His tasks …

Roche has signed a $490 million deal with specialist biotech firm PTC Therapeutics. Roche is paying PTC $30 million upfront …

The HDL drug specialist Cerenis Therapeutics has appointed Dr John Paolini as its new chief medical officer. Dr Paolini will …

Abbott will develop a diagnostic kit for GlaxoSmithKline’s new lung cancer drug candidate.   This is an expansion of a …

Peter Theil has joined UCB as its new vice president and head of non-clinical development for the firm’s new medicines …

 PfizerOf all the patent cliffs in pharma, Lipitor’s expiry represents the biggest. Pfizer is now staring over the precipice, with …

NICE is recommending Pfizer and Bristol-Myers Squibb’s Eliquis for blood clots after surgery. Specifically, NICE has said that Eliquis (apixaban) …

RSA, the global life sciences executive search and interim management firm, has announced a series of new appointments. RSA Switzerland …

Despite the burgeoning interest in Adaptive Trial Design (ATD), an extremely powerful tool when used effectively in the appropriate circumstances, …

The BioIndustry Association (BIA) has appointed Glyn Edwards as its interim chief executive effective immediately. Edwards was previously chief executive …

The National Institute for Health and Clinical Excellence (NICE) has reappointed Professor Sir Michael Rawlins as NICE chairman for a …

Leading pharma firms are getting around 30% less on their investments in research and development compared to last year, according …

Swedish speciality firm Pharmalink AB has elected Anders Wiklund to serve as its new chairman of the board. In addition …

A new cancer survival study shows that pancreatic cancer continues to have one of the worst mortality rates.  The study …